Scientific Publications

Advancing dermatological science.

March 2023 Featured

AAD 2023

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

October 2022 Featured

JAMA

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials

March 2023

AAD 2023

Efficacy and Safety of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials

March 2023

AAD 2023

Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Treatment Patterns and Patient Satisfaction of Seborrheic Dermatitis in the United States: Results from a National Survey

March 2023

British Journal of Dermatology

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

November 2022

American Journal of Clinical Dermatology

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

November 2022

American Journal of Clinical Dermatology

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

September 2022

EADV 2022

Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial

September 2022

EADV 2022

Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial

September 2022

EADV 2022

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download